BetterScholar BetterScholar
Title Claps Level Year L/Y
Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)
45 auth. P. Joly, Barbara Horváth, Α. Patsatsi, S. Uzun, R. Bech, Stefan Beissert, Reuven Bergman, Philippe Bernard, L. Borradori, M. Caproni, F. Caux, G. Cianchini, M. Daneshpazhooh, D. De, M. Dmochowski, ... K. Drenovska, J. Ehrchen, Claudio Feliciani, Matthias Goebeler, Richard W Groves, C. Guenther, Silke C. Hofmann, D. Ioannides, C. Kowalewski, R. Ludwig, Yen Loo Lim, B. Marinović, A. Marzano, A. Marzano, J. Mascaró, D. Mimouni, D. Murrell, C. Pincelli, C. P. Squarcioni, Miklós Sárdy, J. Setterfield, Eli Sprecher, Eli Sprecher, S. Vassileva, K. Woźniak, S. Yaylı, G. Zambruno, D. Zillikens, M. Hertl, Enno Schmidt
Pemphigus encompasses a group of life‐threatening autoimmune bullous diseases characterized by blisters and erosions of the mucous membranes and skin. Before the era of immunosuppressive treatment, pemphigus was almost always fatal. Due to its rarit…
Pemphigus encompasses a group of life‐threatening autoimmune bullous diseases characterized by blisters and erosions of the mucous membranes and skin. Before the era of immunosuppressive treatment, pemphigus was almost always fatal. Due to its rarity, only few randomized controlled therapeutic trials are available. Recently, rituximab has been approved as first‐line treatment for moderate and severe pemphigus vulgaris in Europe and the United States.
Published in Journal of the European Academy of Dermatology and Venereology
2
 7 2020